

AMENDMENTS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of claims:

1. (previously presented) A pharmaceutical composition of matter in the form of a solution concentrate comprising a cyclosporin dissolved in dimethyl sulfoxide (DMSO) wherein the concentration of cyclosporin is from 0.1% to 90% by weight of the total composition.

2. (previously presented) A composition as in claim 1 wherein the cyclosporin is cyclosporin A.

3. (currently amended) A method for administering cyclosporin into cerebrospinal fluid spaces of a patient, which comprises:

providing cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution by injection into the cerebrospinal fluid spaces to said patient wherein said

cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

4. (previously presented) A method for administering cyclosporin by injection including intra-ocular, intravestibular, into or adjacent to the brain or spinal cord to a patient, the improvement which comprises: providing cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution by injection intra-ocular, intravestibular, into or adjacent to the brain, or spinal cord to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

5. (previously presented) A method for administering cyclosporin by injection including intravenous, intra-arterial or intraparenchymal, into a patient, the improvement which comprises: providing cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution by injection into intravenous, intra-arterial or intraparenchymal spaces to said patient

wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

6. (currently amended) A method for administering cyclosporin orally, inhalationally ~~(See PCT page 5 Medicament and Administration)~~ rectally, vaginally, urethrally, bladder cisternally, ~~(same reference)~~, nasally, intra and peri-ocularly ~~(PCT page 5 medicament and Administration: "intra and peri-ocular instillation including application by injection around the eye, within the eyeball, its structures and layers")~~ or dermally to a patient, ~~the improvement which comprises:~~ method comprising providing the cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution orally, inhalationally, rectally, vaginally, urethrally, bladder cisternally, nasally, intra and peri-ocularly or dermally to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

7. (currently amended) The method of claim 3 wherein the cyclosporin is cyclosporin A, ~~or functional derivatives, metabolites, variants~~ or salts thereof.

8. (currently amended) An article of manufacture comprising packaging material and a pharmaceutical agent that is therapeutically effective for reducing or ~~preventing~~ treating neuronal damage and for causing immunosuppression when administered in a therapeutically effective quantity, ~~and~~ wherein the packaging material comprises a label which indicates that the pharmaceutical agent can be used for reducing or ~~preventing~~ treating neuronal damage and for causing immunosuppression, and wherein said pharmaceutical agent comprises DMSO and a one or more cyclosporin cyclosporins ~~or functional derivatives~~ wherein said ~~cyclosporin~~ cyclosporins ~~is~~ are present in an amount of from 0.1 to 90% by weight of the total composition, ~~metabolites, variants or salts thereof, or a combination of the before said,~~ either alone or in admixture with diluents or additives.

9. (currently amended) The article of manufacture according to claim 8, wherein the cyclosporin is selected from the group consisting of cyclosporin A ~~and a compound of the class of cyclosporins.~~

10. (currently amended) The method according to claim 3 wherein the administering of cyclosporin into cerebrospinal fluid spaces is intraventricular ~~and~~ or intrathecal.

11. (currently amended) ~~An improved~~ method for treating Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV neuropathy, Guillain-Barré syndrome, neural transplantation, neural xenotransplantation, stroke, brain hemorrhage, brain and spine trauma, ionizing radiation, neurotoxicity of vestibulocochlear structures, and retinal detachment which comprises administering cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

12. (currently amended) ~~An improved~~ method for inducing systemic immunosuppression in patients with transplantation and autoimmune disease which comprises administering cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and

Application No.: 09/674,092

administering said cyclosporin and DMSO solution to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.